Forbion has raised €183M for its 3rd capital fund – a big win for this top-notch Dutch VC, especially when stock markets are getting ever less friendly.
Forbion is one of the best European VCs in Europe for Biotech. Based primarily near Amsterdam (it also has offices in Munich), it is probably a factor in the success of Biotechs in the Benelux area (Belgium, Netherlands & Luxembourg).
The VC has now raised €183M (around $208M) for its Forbion Capital Fund III (FCF III), its third main fund.
The investment strategy will be similar to the previous fund (FCF II). Therefore, Forbion aims to invest around 70% in Europe – with the rest going to Biotech based in the US and Canada.
As for the kind of Biotechs that will be chosen, the investment focus will remain on private companies developing novel drugs,